Abstract:The esophageal adenocarcinoma (EA) is a highly lethal malignancy with an extremely low survival rate. Effective therapy for EA is currently unavailable due to the limited understanding of its pathophysiology. Barrett's esophagus (BE) is a premalignant condition that is strongly associated with an increased risk for EA. It has been reported that BE and EA patients reflux high concentrations (>150 μM) of bile acids into the esophagus as compared to normal individuals (<20 μM). Bile acids are now recognized as important regulatory molecules, which activate different cell signaling pathways based on conjugation state and hydrophobicity. Our previous studies reported that conjugated bile acids (CBA), taurocholic acid (TCA) and glycocholic acid (GCA), but not unconjugated bile acids are able to activate growth promoting and tumorigenic cell signaling pathways by activating the sphingosine‐1‐phosphate receptor 2 (S1PR2) in cholangiocarcinoma cells. S1PR2 also has been linked to activation of sphingosine kinase 2 (sphK2). However, the role of S1PR2/SphK2 in bile acid‐mediated proliferation and migration of EA cells is not clear and is the focus of this study. Methods Studies were conducted in the human normal esophagus cell line Het‐1A, BE cell line CP‐A and EA cell lines, OE‐19 and OE‐33. The expression of individual S1PR and SphK was determined by real‐time RT‐PCR and Western blot analysis and confirmed by DNA sequencing. The chemical antagonist of S1PR2, JTE‐013, Sphk2 inhibitor, K145, and gene‐specific shRNAs were used to inhibit S1PR2/SphK2 activation and expression. Cell proliferation was determined using a CCK‐8 kit. The Wound‐Healing assay and invasion assay were used to examine cell migration and invasion. Anchorage independent growth was examined using soft agar colony formation assay. TCGA and GEO databases were used to investigate the clinical relevance of S1PR2/SphK2 in EA disease progression. Results The expression levels of S1PR2 and SphK2 in aggressive EA cell line, OE‐33, were significantly higher than those in normal (Het‐1A) or BE (CP‐A) or the lower grade EA cell line (OE‐19). In addition, S1PR2 was the predominant S1PR in OE‐33 cells. TCA, GCA and S1P significantly induced proliferation, migration, invasion and anchorage‐independent growth of EA cells, which were inhibited by JTE‐013 and K145 as well as gene specific shRNAs targeting S1PR2 and SphK2. Compared to OE‐19, OE‐33 had a stronger response to TCA and S1P. This is consistent with clinical data as EA patients with high SphK2 expression had poor prognosis and high grade dysplasia. Discussion/Conclusion High bile acid level is associated with EA. S1PR1, S1PR2, S1PR3, SphK1 and SphK2 are all expressed in human EA cancer cells. However, S1PR2 and SphK2 expression levels are much higher than those of S1PR1, S1PR3 and SphK1. In this study, by using chemical antagonists and gene‐specific shRNAs, we were able to show that S1PR2 and SphK2 play critical roles in conjugated bile acid/S1P‐mediated invasive growth of EA cells. The results in this study suggest that targeting S1PR2/SphK2 may represent a novel therapy for EA.

The Role of Sphingosine 1‐phosphate Receptor 2 in Bile‐acid–induced Cholangiocyte Proliferation and Cholestasis‐induced Liver Injury in Mice

Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes.

Sphingosine kinase 2 plays a critical role in bile acid‐induced cholestatic liver injury <i>via</i> regulating miR‐155 and macrophage activation

Reversal of cholestatic liver disease by the inhibition of sphingosine 1-phosphate receptor 2 signaling

Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression.

Conjugated Bile Acids Promote Cholangiocarcinoma Cell Invasive Growth Through Activation of Sphingosine 1-Phosphate Receptor 2.

Sphingosine 1-Phosphate Receptor 2 and 3 Mediate Bone Marrow-Derived Monocyte/Macrophage Motility in Cholestatic Liver Injury in Mice

Taurocholic Acid Promotes Hepatic Stellate Cell Activation Via S1PR2/p38 MAPK/YAP Signaling under Cholestatic Conditions

Modulating intestinal barrier function by sphingosine-1-phosphate receptor 1 specific agonist SEW2871 attenuated ANIT-induced cholestatic hepatitis via the gut-liver axis

A novel model to study mechanisms of cholestasis in human cholangiocytes reveals a role for the SIPR2 pathway

Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway

NLRP3 inflammasome priming and activation in cholestatic liver injury via the sphingosine 1-phosphate/S1P receptor 2/Gα(12/13)/MAPK signaling pathway

Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis

Clonorchis sinensis infection induces hepatobiliary injury via disturbing sphingolipid metabolism and activating sphingosine 1-phosphate receptor 2

Taurocholate Induces Cyclooxygenase-2 Expression Via the Sphingosine 1-Phosphate Receptor 2 in A Human Cholangiocarcinoma Cell Line

Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism

IDDF2024-ABS-0207 S1P/S1PR4 Promotes the Differentiation of CD8+TRM Cells Aggravating Bile Duct Injury in Biliary Atresia

Bile acid–activated macrophages promote biliary epithelial cell proliferation through integrin αvβ6 upregulation following liver injury

Conjugated bile acids promote esophageal adenocarcinoma cell invasive growth via activation of sphingosine 1‐phosphate receptor 2 and sphingosine kinase 2

SEW2871 Attenuates ANIT-induced Hepatotoxicity by Protecting Liver Barrier Function Via Sphingosine 1-Phosphate Receptor-1–Mediated AMPK Signaling Pathway

Cholangiocytes-Specific Deletion of Sphingosine-1-phospholipid Receptor 1 Attenuate Cholestasis Induced Liver Injury and Fibrosis